| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Gain Therapeutics, Inc. | CFO and Interim CEO | Employee Stock Option (right to buy) | 200K | $1.17M | $5.86 | Apr 8, 2024 | Direct |
| Gain Therapeutics, Inc. | CFO and Interim CEO | Common Stock | 14.4K | $14.5K | $1.01 | Aug 9, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| GANX | Gain Therapeutics, Inc. | Aug 9, 2024 | 1 | $14.5K | 4 | Aug 12, 2024 | CFO and Interim CEO |
| GANX | Gain Therapeutics, Inc. | Apr 8, 2024 | 1 | $0 | 4 | Apr 8, 2024 | Chief Financial Officer |
| GANX | Gain Therapeutics, Inc. | Apr 5, 2024 | 0 | $0 | 3 | Apr 8, 2024 | Chief Financial Officer |